NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM Study
NCT06593327
This study is recruiting at 3 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
A pragmatic, randomized clinical trial to evaluate the effect of a heart failure (HF) risk assessment and prevention strategy incorporating HF clinical risk scores (WATCH-DM) with cardiac biomarker (NT-proBNP) paired with a clinical decision support tool to implement an intensive prevention strategy among patients with high risk focused on implementation of evidence-based HF preventive therapies.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Type 2 Diabetes
- Diabetic Cardiomyopathy
- Heart Failure
- Cardiometabolic Diseases
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- Any age
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- University of Texas Southwestern Medical Center
- Last updated on ClinicalTrials.gov
- September 29, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Texas · 3
- Baylor Scott and White - Health System · Dallas, TX
- Parkland Health & Hospital System (PHHS) · Dallas, TX
- University of Texas Southwestern Medical Center · Dallas, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.